Monday, July 24, 2006
BARRON'S (WALLSTREETS $4 PUMP RAG)
FRONT PAGE:
TIME TO BUY
has always been dead wrong and that my dear is the sell signal.
motley fool is also trying the superthick pump of ignarance on PDLI
june 19th
http://www.fool.com/news/commentary/2006/commentary06061906.htm?source=eptyholnk303100&logvisit=y&npu=y
And there's also PDL BioPharma (Nasdaq: PDLI) . It has shed roughly a third of its value in the past six weeks because of ... nothing. The downdraft is so ludicrous that company director Jon Saxe, who has a history of selling shares, recently acquired 70,000 stubs through options that he's still holding. Had he sold immediately, he would be sitting on a triple right now. My guess is that he sees plenty more upside ahead."
lol- they missed at the wrong time, and the option issue is just sugarand they are buying ON THE CHEAP VIA OPTIONS NOT COLD HARD CASH. if wallstreet can keep the sugar pouring it can fill the gap,, but PDLI has to hit something big out of the ballpark and sooooon. otherwise this just another timed option issue. bet they try the KLAC 'forecast better pump' (off of lower levels now established.)scalp value not a marriage.
http://biz.yahoo.com/ap/060502/earns_pdl_biopharma.html?.v=1
may 2 WHAT PART OF CUT DOES MOTLEY FOOL NOT UNDERSTAND?
Revenue grew to $90.5 million from $38.8 million last year from the recent acquisition of ESP Pharma and Retavase.
Analysts surveyed by Thomson Financial expected earnings per share of 14 cents on revenue of $103.3 million.
PDL also cut its forecast revenue range by $5 million to between $400 million and $430 million for the year.
TIME TO BUY
has always been dead wrong and that my dear is the sell signal.
motley fool is also trying the superthick pump of ignarance on PDLI
june 19th
http://www.fool.com/news/commentary/2006/commentary06061906.htm?source=eptyholnk303100&logvisit=y&npu=y
And there's also PDL BioPharma (Nasdaq: PDLI) . It has shed roughly a third of its value in the past six weeks because of ... nothing. The downdraft is so ludicrous that company director Jon Saxe, who has a history of selling shares, recently acquired 70,000 stubs through options that he's still holding. Had he sold immediately, he would be sitting on a triple right now. My guess is that he sees plenty more upside ahead."
lol- they missed at the wrong time, and the option issue is just sugarand they are buying ON THE CHEAP VIA OPTIONS NOT COLD HARD CASH. if wallstreet can keep the sugar pouring it can fill the gap,, but PDLI has to hit something big out of the ballpark and sooooon. otherwise this just another timed option issue. bet they try the KLAC 'forecast better pump' (off of lower levels now established.)scalp value not a marriage.
http://biz.yahoo.com/ap/060502/earns_pdl_biopharma.html?.v=1
may 2 WHAT PART OF CUT DOES MOTLEY FOOL NOT UNDERSTAND?
Revenue grew to $90.5 million from $38.8 million last year from the recent acquisition of ESP Pharma and Retavase.
Analysts surveyed by Thomson Financial expected earnings per share of 14 cents on revenue of $103.3 million.
PDL also cut its forecast revenue range by $5 million to between $400 million and $430 million for the year.
# posted by tagthatstock @ 3:15 AM
